Given our discovery of a gene causing a disease with EA2 symptoms in a patient bearing an ATP1A2 mutation, this seems likely, and perhaps the use of whole‐exome or genome sequencing approaches will enhance the probability of identifying new genes and/or mutations responsible for EA2 to allow future improvement of EA2 diagnostics. The gene discussed is ATP1A2; the disease is episodic ataxia type 2.